Aleglitazar
| CAS No. | 475479-34-6 | Cat. No. | BCP11370 |
| Name | Aleglitazar | ||
| Synonyms | R1439;RO0728804;R-1439;RO-0728804;R 1439;RO 0728804; RG-1439; R-1439; R 1439;; | ||
| Formula | C24H23NO5S | M. Wt | 437.51 |
| Description | Aleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones. | ||
| Pathways | Cell Cycle/DNA Damage | ||
| Targets | PPAR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.